In melanoma-bearing mouse models, fusion of IL-2 with an antibody specific for GD2 inhibited lung and liver metastases and prolonged survival following lymphokine-activated killer (LAK) cell reconstitution in immunocompromised mice, compared to unconjugated IL-2 administration (13). This evidence concerns the gene IL2 and melanoma.